Anebulo Pharmaceuticals (FRA:214) Additional Paid-In Capital : €63.49 Mil(As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Additional Paid-In Capital?

Anebulo Pharmaceuticals's quarterly additional paid-in capital declined from Sep. 2023 (€63.71 Mil) to Dec. 2023 (€63.15 Mil) but then increased from Dec. 2023 (€63.15 Mil) to Mar. 2024 (€63.49 Mil).

Anebulo Pharmaceuticals's annual additional paid-in capital increased from Jun. 2021 (€49.83 Mil) to Jun. 2022 (€57.25 Mil) and increased from Jun. 2022 (€57.25 Mil) to Jun. 2023 (€62.56 Mil).

Anebulo Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Anebulo Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Additional Paid-In Capital Chart

Anebulo Pharmaceuticals Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Additional Paid-In Capital

49.83

57.25

62.56

Anebulo Pharmaceuticals Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial										63.16	62.56	63.71	63.15	63.49

Anebulo Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Anebulo Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Anebulo Pharmaceuticals (FRA:214) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (FRA:214) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ANEB:USA

Address

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734

Website

https://www.anebulo.com

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Anebulo Pharmaceuticals (FRA:214) Headlines

No Headlines